Pilot Trial of High-dose vitamin C in critically ill COVID-19 patients

8/10 Late treatment study

Zhang et al., Research Square, doi:10.21203/rs.3.rs-52778/v2 (Preprint)
Pilot Trial of High-dose vitamin C in critically ill COVID-19 patients

Source PDF Share Tweet

Small RCT for high dose vitamin C for ICU patients showing reduced (but not statistically significant) mortality. Dosage was 12g of vitamin C/50ml every 12 hours for 7 days at a rate of 12ml/hour.

Zhang et al., 8/10/2020, Randomized Controlled Trial, China, Asia, preprint, 11 authors.

risk of death, 50.0% lower, RR 0.50, p = 0.31, treatment 6 of 27 (22.2%), control 11 of 29 (37.9%), adjusted per study, 28 day mortality.

risk of death, 70.0% lower, RR 0.30, p = 0.07, treatment 5 of 27 (18.5%), control 10 of 29 (34.5%), adjusted per study, 28 day mortality for SOFA>=3.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 18 studies

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit